


***Remarks***

Upon entry of the foregoing amendment, claims 21-26 are pending in the application, with claims 21-26 being the independent claims. The claims have been amended to include sequence identifiers. These changes are believed to introduce no new matter, and their entry is respectfully requested.

It is believed that the application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

 #36,682  
fi Helene C. Carlson  
Agent for Applicants  
Registration No. 47,473

Date: 3/14/03

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

**Version with markings to show changes made**

***In the Claims:***

*Pending claim 21 was replaced with the following claim 21.*

21. (Once amended) An isolated nonapeptide having the amino acid sequence  
EVDPIGHL Y (SEQ ID NO:519).

*Pending claim 22 was replaced with the following claim 22.*

22. (Once amended) An isolated nonapeptide consisting of the amino acid  
sequence EVDPIGHL Y (SEQ ID NO:519).

*Pending claim 23 was replaced with the following claim 23.*

23. (Once amended) An isolated nucleic acid molecule consisting of a nucleotide  
sequence encoding the nonapeptide EVDPIGHL Y (SEQ ID NO:519).

*Pending claim 24 was replaced with the following claim 24.*


24. (Once amended) An isolated cytolytic T cell line which specifically  
recognizes a complex of an HLA-A1 molecule and a nonapeptide having the amino acid  
sequence EVDPIGHL Y (SEQ ID NO:519).

*Pending claim 25 was replaced with the following claim 25.*

25. (Once amended) An isolated cytolytic T cell line which specifically recognizes a complex of an HLA-A1 molecule and a nonapeptide consisting of the amino acid sequence EVDPIGHL Y (SEQ ID NO:519).

*Pending claim 26 was replaced with the following claim 26.*

26. (Once amended) An isolated antigenic HLA-A1 binding peptide derived from a MAGE protein having the following formula:



wherein Xaa<sub>3</sub> is Asp or Glu, and Xaa<sub>9</sub> is Tyr, and

said isolated peptide provides lysis by cytotoxic T cells specific for a complex of said HLA molecule and said nonapeptide, with the proviso that said nonapeptide is not EADPTGHSY (SEQ ID NO:27).